The Guardian
Email YouTube Facebook Instagram Twitter
 
News : Business

Why Amgen thinks Celgene’s Psoriasis drug Otezla is worth $13.4 Billion

By Bloomberg
30 Aug 2019   |   2:42 pm   |  
Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co. Bloomberg's Kailey Leinz reports on "Balance of Power."


Share:

You may also like